our Premium Content: News alerts, weekly reports and conference planners

GENE:

DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A)

News alerts, weekly reports and conference planners

CircDYRK1A Suppresses Gastric Cancer Progression via Sponging miR-331-5p to Regulate GADD45A. (PubMed, J Biochem Mol Toxicol)

The research results showed that circDYRK1A was significantly down-regulated in GC and inhibited the proliferation, migration and invasion of GC cells by the miR-331-5p/GADD45A axis. This study lays a theoretical foundation for the molecular mechanism by which circDYRK1A inhibits the progression of GC and opens up new potential therapeutic approaches for targeted treatment of GC.

1 month ago

Journal

MIR331 (MicroRNA 331) • DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A)

2ms

FAM117B Promotes Colorectal Cancer Progression by Enhancing DYRK1A-mediated Phosphorylation of PLK2. (PubMed, Cell Biol Int)

In conclusion, FAM117B promoted the pathological progression of CRC through enhancing the DYRK1A/PLK2 signaling pathway. Our study provided insights for potential therapeutic strategies against CRC.

2 months ago

Journal

PLK2 (Polo Like Kinase 2) • DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A)

3ms

Novel small-molecule inhibitors of the protein kinase DYRK: Potential therapeutic candidates in cancer. (PubMed, bioRxiv)

Both compounds crossed the blood-brain barrier and suppressed tumor growth, to prolong survival in intracranial xenografts. These findings identify FC-2 and FC-3 as selective small-molecule inhibitors of DYRK1A with potential therapeutic utility in GBM.

3 months ago

Journal

EGFR (Epidermal growth factor receptor) • DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A)

6ms

Harmine suppresses pancreatic cancer through DYRK1A-mediated hyper-activated RAS/MAPK inhibition. (PubMed, Biochem Pharmacol)

Recently, small molecule inhibitors like MRTX1133, which target KRAS G12D, have shown efficacy in inhibiting PC growth...The loss-of-function mutation in mbk-1 (DYRK1A homologous gene) could inhibit the multivulva (Muv) phenotype in nematodes with KRAS G12D. Collectively, our findings indicate that HM could suppress the RAS/MAPK pathway by inhibiting DYRK1A kinase activity, suggesting that DYRK1A could serve as a therapeutic target for PC treatment.

6 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A)

KRAS G12D • RAS mutation

MRTX1133

8ms

Harmine-mediated Reduction of Bone Cancer Pain in Rats Correlates With Suppressed DYRK1A/NF-κB Signaling Axis. (PubMed, J Integr Neurosci)

These findings suggest that Harmine has significant therapeutic potential for alleviating BCP hyperalgesia, providing a foundation for the future development of new drugs targeting BCP.

8 months ago

Preclinical • Journal

DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A)

8ms

Mechanism of DYRK1A in Cytarabine Resistance in Acute Myeloid Leukemia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)

DYRK1A is involved in Ara-C resistance in AML cells, and its mechanism may be related to increased expression of SAMHD1 by interacting with Cyclin L2.

8 months ago

Journal

SAMHD1 (SAM And HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1) • DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A)

cytarabine

8ms

Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A. (PubMed, Nat Genet)

Collectively, these findings define chr. 21amp as a prognostic biomarker in BP-MPN, and link chromothripsis to a therapeutic target.

8 months ago

Journal

DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A)

1year

Analysis of 1386 epileptogenic brain lesions reveals association with DYRK1A and EGFR. (PubMed, Nat Commun)

Here we confirm four known associations (BRAF, SLC35A2, MTOR, PTPN11), support eight associations without prior statistical support (FGFR1, PIK3CA, AKT3, NF1, PTEN, RHEB, KRAS, NRAS), and identify novel associations for two genes, DYRK1A and EGFR. Both novel genes show specific histopathological phenotypes, interact with LFE genes and pathways, and may represent promising candidates as biomarkers and potentially druggable targets.

1 year ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • FGFR1 (Fibroblast growth factor receptor 1) • NF1 (Neurofibromin 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • SLC35A2 (Solute Carrier Family 35 Member A2) • DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A) • RHEB (Ras Homolog, MTORC1 Binding)

over1year

Differential regulation of expression of the protein kinases DYRK1A and DYRK1B in cancer cells. (PubMed, Sci Rep)

Consistently, AURK inhibitors VX-680 (tozasertib), MLN8237 (alisertib), AZD1152-HQPA (barasertib) resulted in the upregulation of DYRK1B expression in A549 cells. In summary, our findings indicate that the expression of DYRK1A and DYRK1B is differentially regulated in cancer cells and reveal that the kinase inhibitor XMU-MP-1 increases DYRK1B expression likely through off target inhibition of Aurora kinases.

over 1 year ago

Journal

AURKA (Aurora kinase A) • AURKB (Aurora Kinase B) • DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A) • DYRK1B (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B)

alisertib (MLN8237) • barasertib-HQPA (AZD2811) • tozasertib (MK-0457)

over1year

Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. (PubMed, NPJ Precis Oncol)

Furthermore, we show that accumulation of cancer cells in G1/S upon DYRK1A inhibition led to significant potentiation of G1/S targeting chemotherapy drug responses in vitro and in vivo. This study underscores the potential for developing novel DYRK1A-targeting therapies in colon and breast cancers and, at the same time, further defines DYRK1A pharmacological inhibition as a viable and powerful combinatorial treatment approach for improving G1/S targeting chemotherapy drugs treatments in solid tumors.

over 1 year ago

Journal

DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A)

almost2years

MicroRNA-298 determines the radio-resistance of colorectal cancer cells by directly targeting human dual-specificity tyrosine(Y)-regulated kinase 1A. (PubMed, World J Gastrointest Oncol)

Taken together, our findings underline the role played by miR-298 in bolstering radio-resistance in CRC cells by means of DYRK1A downregulation, thereby positioning miR-298 as a promising candidate for mitigating radio-resistance in CRC.

almost 2 years ago

Journal

DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A)

almost2years

Gene Expression Studies in Down Syndrome: What Do They Tell Us about Disease Phenotypes? (PubMed, Int J Mol Sci)

Understanding the differential expression of genes provides insights into the genetic consequences of DS. A better understanding of these processes could potentially pave the way for the development of genetic and pharmacological therapies.

almost 2 years ago

Review • Journal

RUNX1 (RUNX Family Transcription Factor 1) • DNMT3B (DNA Methyltransferase 3 Beta) • STAT1 (Signal Transducer And Activator Of Transcription 1) • COL6A1 (Collagen Type VI Alpha 1 Chain) • ITGB2 (Integrin Subunit Beta 2) • TBX1 (T-Box Transcription Factor 1) • CLIC6 (Chloride Intracellular Channel 6) • DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A) • GSTT1 (Glutathione S-transferase theta 1) • OLIG2 (Oligodendrocyte Transcription Factor 2) • SIK1 (Salt Inducible Kinase 1) • XIST (X Inactive Specific Transcript)